Autobio Diagnostics Co., Ltd.
603658
Rangering i aksjer
#4904
Autobio Diagnostics Co., Ltd. specializes in the full lifecycle of clinical... Autobio Diagnostics Co., Ltd. specializes in the full lifecycle of clinical diagnostic products, from their initial research and development to manufacturing and market distribution. Their diverse offerings encompass a range of reagents for immunoassay, biochemistry, microbiology, and in-vitro diagnostics (IVD). Additionally, they provide advanced automated and semi-automated instrumentation, alongside comprehensive medical laboratory solutions. Notable immunoassay products include the AutoLumo A2000 Plus automatic chemiluminescence immunoassay analyzer, automated microplate chemiluminescent enzyme immunoassays, LUmo luminometers, PHOmo microplate readers, and iWO microplate washers. Within their microbiology division, they offer automated blood culture systems, blood culture bottles, AUTOMIC strips, and mycoplasma IES. Founded in 1998, the company originally operated as Lifeclone Diagnostics Co., Ltd. before adopting its current name, Autobio Diagnostics Co., Ltd., in 2003. Headquartered in Zhengzhou, China, it functions as a subsidiary of Zhengzhou Auto Industrial Co., Ltd.
Aksjekurs
$5.15
Sist synkronisert: 2026-10-22
Markedsverdi
$2.94B
Endring (1 dag)
0.97%
Endring (1 år)
-5.80%
Land
CN
Handel Autobio Diagnostics Co., Ltd. (603658)
Kategori
Healthcare
Inntekter for Autobio Diagnostics Co., Ltd. (603658)
Inntekter i Jun 2026 TTM: $169.22M
Ifølge Autobio Diagnostics Co., Ltd. sine nyeste økonomiske rapporter er selskapets nåværende resultat $169.22M. I 2024 hadde selskapet et resultat på $176.60M, en nedgang sammenlignet med resultatet i 2023, som var $192.49M. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Autobio Diagnostics Co., Ltd. fra 2011 til 2026
Inntekter ved slutten av hvert år
| År | Inntekter | Endre |
|---|---|---|
| 2026 (TTM) | $169.22M | -3.17% |
| 2025 | $174.77M | -1.04% |
| 2024 | $176.60M | -8.25% |
| 2023 | $192.49M | 2.63% |
| 2022 | $187.55M | 11.87% |
| 2021 | $167.65M | 29.68% |
| 2020 | $129.28M | 1.63% |
| 2019 | $127.20M | 33.67% |
| 2018 | $95.16M | 20.21% |
| 2017 | $79.16M | 34.78% |
| 2016 | $58.73M | 17.42% |
| 2015 | $50.02M | 28.06% |
| 2014 | $39.06M | 63.96% |
| 2013 | $23.82M | 27.82% |
| 2012 | $18.64M | 63.64% |
| 2011 | $11.39M | 0.00% |
Inntekter for lignende selskaper eller konkurrenter
| Selskap | Inntekter | Forskjell i inntekter | Land |
|---|---|---|---|
| $7.87B | 4,550.10% |
US
|
|
| $4.82B | 2,747.14% |
US
|
|
| $-252.70M | -249.33% |
US
|
|
| $4.12B | 2,335.02% |
CN
|
|
| $1.66B | 879.78% |
US
|
